BioNTech SE (BNTX) — SEC Filings

Latest SEC filings for BioNTech SE (BNTX), explained in plain English.

Sentiment Overview: 12 bullish, 3 bearish, 35 neutral

Recent Filings (50)

• BioNTech Completes CureVac Share Exchange Offer — 6-K · 2025-12-18T00:00:00.000Z [bullish] Risk: medium
  On December 18, 2025, BioNTech SE announced the expiration of the subsequent offering period and the successful completion of its exchange offer for all outstan
• 6-K Filing — 6-K · 2025-12-09T00:00:00.000Z [neutral]
• BioNTech SE Files Form 6-K for December 2025 — 6-K · 2025-12-08T00:00:00.000Z [neutral] Risk: low
  On December 6, 2025, BioNTech SE and OncoC4, Inc. presented data from their non-pivotal study. The filing is a Form 6-K, indicating it's a report of a foreign p
• 6-K Filing — 6-K · 2025-12-03T00:00:00.000Z [neutral]
• 6-K Filing — 6-K · 2025-11-26T00:00:00.000Z [neutral]
• BioNTech SE Hosts Innovation Series R&D Day — 6-K · 2025-11-12T00:00:00.000Z [neutral] Risk: low
  On November 11, 2025, BioNTech SE hosted its Innovation Series R&D Day, presenting an overview of its research and development pipeline. The company, headquarte
• BioNTech SE Reports Q3 2025 Results — 6-K · 2025-11-03T00:00:00.000Z [neutral] Risk: low
  BioNTech SE announced its third quarter 2025 financial results and corporate update on November 3, 2025. The company is a German biotechnology firm headquartere
• BioNTech Launches Exchange Offer for CureVac Shares — 6-K · 2025-10-22T00:00:00.000Z [neutral] Risk: medium
  On October 22, 2025, BioNTech SE announced the commencement of an exchange offer for all outstanding shares of CureVac N.V. This filing is a Form 6-K report sub
• BioNTech Hosts Second AI Day with InstaDeep — 6-K · 2025-10-01T00:00:00.000Z [neutral] Risk: low
  On October 1, 2025, BioNTech SE, in collaboration with its AI subsidiary InstaDeep Ltd., held its second AI Day. This event showcased advancements and future di
• BioNTech SE Enters Global Co-Development Deal — 6-K · 2025-09-08T00:00:00.000Z [neutral] Risk: medium
  On June 2, 2025, BioNTech SE entered into a Global Co-Development and Commercialization Agreement with an unnamed partner. This agreement outlines the terms for
• BioNTech SE Files Form 6-K for September 2025 — 6-K · 2025-09-05T00:00:00.000Z [neutral] Risk: low
  On September 5, 2025, BioNTech SE announced a collaboration with Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") regarding a pivotal Phase 3 trial, identifi
• BioNTech/Pfizer COVID Vaccine Approved for Young Children — 6-K · 2025-08-27T00:00:00.000Z [bullish] Risk: low
  On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved their supplemental Biologics License Applica
• BioNTech SE Reports Ongoing Disputes with CureVac N.V. — 6-K · 2025-08-11T00:00:00.000Z [neutral] Risk: medium
  BioNTech SE filed a Form 6-K on August 11, 2025, reporting ongoing disputes with CureVac N.V. and CureVac SE. The filing indicates that BioNTech and its subsidi
• BioNTech SE Reports Q2 2025 Financial Results — 6-K · 2025-08-04T00:00:00.000Z [neutral] Risk: low
  On August 4, 2025, BioNTech SE announced its second quarter 2025 financial results and provided a corporate update. The company is a German biotechnology firm f
• BioNTech/Pfizer Vaccine Gets EMA Nod for 2025-26 Season — 6-K · 2025-07-25T00:00:00.000Z [bullish] Risk: low
  On July 25, 2025, BioNTech SE and Pfizer Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended t
• BioNTech SE Announces CSO Ryan Richardson's Departure — 6-K · 2025-07-17T00:00:00.000Z [neutral] Risk: low
  On July 17, 2025, BioNTech SE announced that Ryan Richardson will be stepping down from his role as Chief Strategy Officer. The company filed a Form 6-K to repo
• BioNTech SE Files 6-K with Purchase Agreement Details — 6-K · 2025-06-17T00:00:00.000Z [neutral] Risk: low
  On June 12, 2025, BioNTech SE entered into a Purchase Agreement, the details of which are included as part of this Form 6-K filing. The company is a European st
• BioNTech SE Files Updated Articles of Association — 6-K · 2025-06-17T00:00:00.000Z [neutral] Risk: low
  BioNTech SE filed a Form 6-K on June 17, 2025, to report an English translation of its current Articles of Association. These updated articles were registered w
• BioNTech SE Enters Purchase Agreement with CureVac N.V. — 6-K · 2025-06-12T00:00:00.000Z [neutral] Risk: low
  On June 12, 2025, BioNTech SE announced a Purchase Agreement with CureVac N.V., also dated June 12, 2025. This agreement was detailed in a joint press release i
• BioNTech SE Announces Collaboration with Bristol Myers Squibb — 6-K · 2025-06-02T00:00:00.000Z [neutral] Risk: low
  On June 2, 2025, BioNTech SE (BNTX) and Bristol Myers Squibb (BMY) announced a collaboration. The specific details of this collaboration, including any financia
• BioNTech SE to Present Pipeline Clinical Trial Data — 6-K · 2025-05-27T00:00:00.000Z [neutral] Risk: low
  On May 27, 2025, BioNTech SE announced it will present clinical trial data from its pipeline candidates at an upcoming event. The company, headquartered in Main
• BioNTech Secures UK Government Grant for R&D Expansion — 6-K · 2025-05-20T00:00:00.000Z [bullish] Risk: low
  On May 20, 2025, BioNTech SE announced that its subsidiary, BioNTech UK Ltd., has entered into a grant agreement with the UK Government. This agreement aims to
• BioNTech SE Holds 2025 Annual General Meeting — 6-K · 2025-05-16T00:00:00.000Z [neutral] Risk: low
  On May 16, 2025, BioNTech SE held its Annual General Meeting (AGM) 2025. The company attached the AGM presentation as Exhibit 99.1 and also provided the voting
• BioNTech Appoints New CFO — 6-K · 2025-05-05T00:00:00.000Z [neutral] Risk: low
  On May 5, 2025, BioNTech SE announced the appointment of Ramó n Zapata-Gomez to its Management Board as Chief Financial Officer, effective immediately. This app
• BioNTech to Present Oncology Pipeline Data at AACR Meeting — 6-K · 2025-04-24T00:00:00.000Z [neutral] Risk: low
  On April 24, 2025, BioNTech SE announced its upcoming presentation of data for several oncology pipeline assets, including mRNA cancer immunotherapies. The comp
• BioNTech SE Announces 2025 Annual General Meeting Date — 6-K · 2025-04-04T00:00:00.000Z [neutral] Risk: low
  BioNTech SE announced on April 4, 2025, that its Annual General Meeting (AGM) for 2025 will be held on May 16, 2025. The company published the invitation to thi
• BioNTech SE Files Form 6-K with SEC — 6-K · 2025-04-02T00:00:00.000Z [neutral] Risk: low
  BioNTech SE announced on April 2, 2025, that it entered into a binding term sheet on December 23, 2024. The filing is a Form 6-K, which is a report of a foreign
• BioNTech SE Files 2024 Annual Report — 20-F · 2025-03-10T00:00:00.000Z [neutral] Risk: medium
  BioNTech SE filed its 20-F annual report for the fiscal year ending December 31, 2024. The report details the company's financial performance and business opera
• BioNTech's BNT141 Vaccine Candidate Faces FDA Clinical Hold — 6-K · 2025-03-04T00:00:00.000Z [bearish] Risk: medium
  On March 4, 2025, BioNTech SE was informed by the U.S. Food and Drug Administration (FDA) that it has placed a clinical hold on BioNTech's investigational new d
• BioNTech Acquires Biotheus to Boost Oncology Pipeline — 6-K · 2025-02-03T00:00:00.000Z [bullish] Risk: low
  On February 3, 2025, BioNTech SE announced the successful acquisition of Biotheus, a clinical-stage biotechnology company focused on developing novel antibody-b
• BioNTech Outlines 2025 Strategy at J.P. Morgan Conference — 6-K · 2025-01-14T00:00:00.000Z [neutral] Risk: low
  On January 14, 2025, BioNTech SE presented its 2025 strategic priorities at the 43rd annual J.P. Morgan Healthcare Conference. The company, headquartered in Mai
• BioNTech SE Files 6-K, Discusses NIH Talks — 6-K · 2024-12-27T00:00:00.000Z [neutral] Risk: low
  BioNTech SE filed a Form 6-K on December 27, 2024, reporting its activities for the month of December 2024. The filing indicates that the company is in discussi
• BioNTech Partner's Drug IND Application Placed on Clinical Hold — 6-K · 2024-12-13T00:00:00.000Z [bearish] Risk: medium
  BioNTech SE announced on December 13, 2024, that its partner OncoC4, Inc. has been informed by the U.S. Food and Drug Administration (FDA) regarding the investi
• BioNTech Hosts Innovation Series Day — 6-K · 2024-11-14T00:00:00.000Z [neutral] Risk: low
  On November 14, 2024, BioNTech SE is holding its Innovation Series Day, presenting updates on its pipeline and strategic initiatives. The details of this event
• SC 13G/A Filing — SC 13G/A · 2024-11-13T00:00:00.000Z [neutral]
• BioNTech to Acquire Clinical-Stage Biopharma Biotheus — 6-K · 2024-11-13T00:00:00.000Z [neutral] Risk: medium
  On November 13, 2024, BioNTech SE announced the signing of a definitive agreement to acquire Biotheus, a clinical-stage biopharmaceutical company. This acquisit
• BioNTech SE Reports Q3 2024 Financial Results — 6-K · 2024-11-04T00:00:00.000Z [neutral] Risk: low
  BioNTech SE announced its third quarter 2024 financial results on November 4, 2024. The company, headquartered in Mainz, Germany, is a foreign private issuer fi
• BioNTech Partner's Drug Candidate Faces FDA Clinical Hold — 6-K · 2024-10-18T00:00:00.000Z [bearish] Risk: medium
  BioNTech SE announced on October 18, 2024, that its partner OncoC4, Inc. has been informed by the U.S. Food and Drug Administration (FDA) regarding the investig
• BioNTech Showcases AI Progress at AI Day — 6-K · 2024-10-01T00:00:00.000Z [neutral] Risk: low
  On October 1, 2024, BioNTech SE announced its participation in the AI Day presentation, highlighting its advancements in artificial intelligence through its sub
• BioNTech/Pfizer COVID Vaccine Gets EU Panel Recommendation — 6-K · 2024-09-20T00:00:00.000Z [bullish] Risk: low
  On September 20, 2024, BioNTech SE and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of their Om
• BioNTech to Present Oncology Data at ESMO 2024 — 6-K · 2024-09-05T00:00:00.000Z [neutral] Risk: low
  On September 5, 2024, BioNTech SE announced its intention to present clinical trial data for several oncology pipeline assets. The presentations will occur at t
• BioNTech/Pfizer COVID Vaccine Gets FDA Approval for Younger Ages — 6-K · 2024-08-22T00:00:00.000Z [bullish] Risk: low
  On August 22, 2024, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application
• BioNTech Cancer Drug Trial Cleared by FDA — 6-K · 2024-08-19T00:00:00.000Z [bullish] Risk: medium
  On August 19, 2024, BioNTech SE announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its investigational new drug
• BioNTech & Pfizer Announce Phase 3 Vaccine Trial Results — 6-K · 2024-08-16T00:00:00.000Z [neutral] Risk: low
  On August 16, 2024, BioNTech SE and Pfizer Inc. announced top-line results from their Phase 3 clinical trial for a combined vaccine. The filing does not provide
• BioNTech SE Updates on Penn Discussions — 6-K · 2024-08-07T00:00:00.000Z [neutral] Risk: medium
  BioNTech SE is providing an update on its ongoing discussions with the University of Pennsylvania (Penn) regarding intellectual property matters. The company pr
• BioNTech SE Reports Q2 2024 Financial Results — 6-K · 2024-08-05T00:00:00.000Z [neutral] Risk: low
  On August 5, 2024, BioNTech SE announced its second quarter 2024 financial results. The company is a biopharmaceutical firm focused on infectious diseases, canc
• BioNTech SE Announces Positive Phase 2 Data for Influenza Vaccine — 6-K · 2024-07-30T00:00:00.000Z [bullish] Risk: medium
  On July 30, 2024, BioNTech SE announced positive topline data from its Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899). The trial is evaluatin
• BioNTech/Pfizer COVID-19 Vaccine Gets EU CHMP Recommendation — 6-K · 2024-06-28T00:00:00.000Z [bullish] Risk: low
  On June 27, 2024, BioNTech SE and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommen
• BioNTech's Cancer Drug Gets FDA Fast Track — 6-K · 2024-06-24T00:00:00.000Z [bullish] Risk: medium
  On June 24, 2024, BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation
• BioNTech cancer vaccine BNT151 gets FDA green light for Phase 1 trial — 6-K · 2024-06-17T00:00:00.000Z [bullish] Risk: medium
  BioNTech SE announced on June 17, 2024, that its partner MediLink Therapeutics (Suzhou) Co., Ltd. has received clearance from the U.S. Food and Drug Administrat